SILO (SILO Pharma) Cyclically Adjusted Book per Share: $27.99 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SILO SILO Pharma Inc SILO
42 GF Score
Price $2.10
GF Value $3.44
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is SILO Pharma Cyclically Adjusted Book per Share?

SILO Pharma SILO 42 Cyclically Adjusted Book per Share is $27.99 as of Jun. 2026. GuruFocus rates SILO with a GF Score™ of 42/100 and a GF Value™ of $3.44 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

SILO Pharma's adjusted book value per share for the three months ended in Jun. 2026 was $4.328. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $27.99 for the trailing ten years ended in Jun. 2026.

During the past 12 months, SILO Pharma's average Cyclically Adjusted Book Growth Rate was -7.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -1.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 11.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of SILO Pharma was 26.20% per year. The lowest was -1.30% per year. And the median was 11.90% per year.

As of today (2026-09-11), SILO Pharma's current stock price is $2.10. SILO Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $27.99. SILO Pharma's Cyclically Adjusted PB Ratio of today is 0.08.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of SILO Pharma was 22.42. The lowest was 0.08. And the median was 0.94.


SILO Pharma  (NAS:SILO) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

SILO Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.10/27.99
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of SILO Pharma was 22.42. The lowest was 0.08. And the median was 0.94.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


SILO Pharma Cyclically Adjusted Book per Share Related Terms


SILO Pharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for SILO Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SILO Pharma Cyclically Adjusted Book per Share Chart

SILO Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.39 29.70 32.84 31.35 28.58

SILO Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.11 29.47 28.58 28.29 27.99

SILO vs ELAB, GLMD, APVO: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, SILO Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SILO Pharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SILO Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where SILO Pharma's Cyclically Adjusted PB Ratio falls into.


SILO
42GF Score
SILO Pharma Inc SILO
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SILO Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SILO Pharma's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=4.328/333.9520*333.9520
=4.328

Current CPI (Jun. 2026) = 333.9520.

SILO Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201609 14.776 241.428 20.439
201612 12.642 241.432 17.487
201703 23.746 243.801 32.527
201706 22.612 244.955 30.827
201709 14.866 246.819 20.114
201712 17.955 246.524 24.323
201803 18.224 249.554 24.387
201806 13.507 251.989 17.900
201809 14.594 252.439 19.306
201812 13.129 251.233 17.452
201903 9.452 254.202 12.417
201906 3.323 256.143 4.332
201909 -3.258 256.759 -4.237
201912 -0.742 256.974 -0.964
202003 -8.452 258.115 -10.935
202006 20.757 257.797 26.889
202009 18.167 260.280 23.309
202012 11.237 260.474 14.407
202103 37.088 264.877 46.760
202106 28.530 271.696 35.067
202109 76.902 274.310 93.622
202112 68.652 278.802 82.232
202203 63.932 287.504 74.261
202206 59.203 296.311 66.724
202209 56.713 296.808 63.810
202212 49.009 296.797 55.144
202303 44.758 301.836 49.520
202306 40.077 305.109 43.866
202309 36.217 307.789 39.296
202312 31.840 306.746 34.664
202403 28.000 312.332 29.938
202406 24.024 314.175 25.536
202409 22.682 315.301 24.024
202412 16.836 315.605 17.815
202503 13.415 319.799 14.009
202506 8.522 322.561 8.823
202509 7.187 324.800 7.390
202512 7.100 324.054 7.317
202603 5.242 330.213 5.301
202606 4.328 333.952 4.328

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $27.99 mean?
SILO Pharma (SILO) has a Cyclically Adjusted Book per Share of $27.99 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on SILO Pharma and its competitors.
Is SILO Pharma's Cyclically Adjusted Book per Share too high?
SILO Pharma's current Cyclically Adjusted Book per Share is $27.99. Overall, SILO Pharma has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SILO Pharma's Cyclically Adjusted Book per Share compare to ELAB and GLMD?
SILO Pharma's Cyclically Adjusted Book per Share of $27.99 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on SILO Pharma and its competitors. SILO Pharma's current Cyclically Adjusted Book per Share is $27.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SILO Pharma stock overvalued right now?
Based on GuruFocus' analysis, SILO Pharma (SILO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.44, compared to a current price of $2.10 — trading 39% below its estimated fair value. The current Cyclically Adjusted Book per Share is $27.99. SILO Pharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For SILO Pharma (SILO), the current Cyclically Adjusted Book per Share is $27.99 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SILO Pharma (SILO) Overvalued in 2026?

Based on GuruFocus' analysis, SILO Pharma stock appears to be undervalued. The current stock price of $2.10 is trading 39% below its estimated GF Value™ of $3.44. GuruFocus considers SILO Pharma to be Possible Value Trap.

Key valuation signals for SILO:

  • Cyclically Adjusted Book per Share: $27.99
  • GF Value™: $3.44 vs. price of $2.10 (39% below fair value)
  • GF Score™: 42/100 with 3 warning signs

No single metric tells the full story. See the SILO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SILO Pharma Business Description

Address 677 N. Washington Boulevard, Sarasota, FL, USA, 34236
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
42GF Score

Get the complete analysis for SILO

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price
$3.44
GF Value